JGC
DNTH icon

J. Goldman & Co’s Dianthus Therapeutics DNTH Stock Holding History

J. Goldman & Co’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$648K Buy
+7,716
New +$447K 0.02% 479

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

J. Goldman & Co's DNTH Position: Q1 2026 in Review

J. Goldman & Co opened a new position in Dianthus Therapeutics (DNTH) in Q1 2026: 7,716 shares worth $648K. The stake represents 0.02% of the portfolio and ranks #479 among its holdings.

241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • J. Goldman & Co held 7,716 shares of Dianthus Therapeutics worth $648K as of Q1 2026.
  • Dianthus Therapeutics was a new J. Goldman & Co position in Q1 2026.
  • Dianthus Therapeutics made up 0.02% of J. Goldman & Co's portfolio in Q1 2026, its #479 holding.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.